There was, however, no significant difference in overall survival between the 2 treatment arms. The magnitude of the 5T4-specific antibody response post- vaccination was associated with increased patient survival, as seen in previous trials. A second vaccine has also been analyzed in patients with metastatic renal cell carcinoma. The TG4010 vaccine consists of MVA expressing recombinant MUC-1 and IL-2 transgenes. The vaccine was used either alone or in combination with exogenous IFN-α and IL -2.